The Company accounts for its leases under FASB ASC Topic 842, Leases. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use ("ROU") asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease, if applicable, or the Company’s incremental borrowing rate. As the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term.

The Company currently leases certain office equipment and its office and laboratory facilities under non-cancelable operating leases. Rent expense for operating leases is recognized on a straight-line basis over the lease term from the lease

commencement date through the scheduled expiration date. Rent expense totaled $457,000 and $453,000, respectively, for the three months ended July 31, 2026 and 2025. The Company considers its facilities adequate for its current operational needs.

•One University Plaza, Suite 307, Hackensack, New Jersey 07601, which, since November 2011, serves as the Company’s corporate headquarters. The lease expires in November 2026. The Company recognized $20,000 and $19,000, respectively, of rent expense relative to this lease for the three months ended July 31, 2026 and 2025.

•1330 Piccard Drive Suite 025, Rockville, MD 20850, which consists of laboratory and office space where the Company conducts operations related to its primary service offerings. The Company executed the original lease in January 2017. The operating commencement date was August 11, 2017. The lease was amended to expand the premises and extend the expiration date in March 2020 and again in December 2020. In June 2026, the lease was amended once again to extend the expiration date from February 2029 to March 2037. As a result of this amendment, the Company recognized an additional operating ROU asset and related operating lease liability of $6.3 million during the three months ended July 31, 2026. The Company recognized $437,000 and $422,000 of rent expense relative to this lease for the three months ended July 31, 2026 and 2025, respectively.

•VIA LEONE XIII, 14, Milan, Italy, which consisted of laboratory and office space where the Company conducted operations related to its flow cytometry service offerings. During fiscal 2026, the Company exercised its right to terminate the lease early on April 30, 2026 and the Company no longer utilizes a physical site in Italy. The Company recognized $0 and $13,000, respectively, of rent expense relative to this lease for both the three months ended July 31, 2026 and 2025.


	July 31, 2026		April 30, 2026
Operating lease right-of-use assets, net	$	9,675	$	3,697
Current portion of operating lease liabilities	635		1,520
Non-current portion of operating lease liabilities	9,886		2,992

As of July 31, 2026, the weighted average remaining operating lease term and the weighted average discount rate were 10.60 years and 8.75%, respectively. As of July 31, 2025, the weighted average remaining operating lease term and the weighted average discount rate were 3.51 years and 5.89%, respectively.


2027 (remaining)	$	2,243
2028	2,966
2029	2,740
2030	1,990
2031	3,087
Thereafter	19,311
Total undiscounted liabilities	32,337
Less: Imputed interest	(22,086)
Present value of minimum lease payments	$	10,251